-
Tytuł:
-
Pharmacokinetics of Herb-Drug Interactions of Plumbagin and Tazemetostat in Rats by UPLC-MS/MS.
-
Autorzy:
-
Li H; Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People's Republic of China.
Wang YJ; Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People's Republic of China.
Geng XN; Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People's Republic of China.
Kang YR; Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People's Republic of China.
Wang YL; Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People's Republic of China.
Qiu XJ; Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People's Republic of China.; Functional Experiment Teaching Center, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People's Republic of China.
-
Źródło:
-
Drug design, development and therapy [Drug Des Devel Ther] 2022 Sep 29; Vol. 16, pp. 3385-3394. Date of Electronic Publication: 2022 Sep 29 (Print Publication: 2022).
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: [Auckland, N.Z.] : Dove Press Limited
-
MeSH Terms:
-
Herb-Drug Interactions*
Tandem Mass Spectrometry*/methods
Acetonitriles ; Animals ; Benzamides ; Biphenyl Compounds ; Carboxymethylcellulose Sodium ; Chromatography, High Pressure Liquid/methods ; Chromatography, Liquid ; Morpholines ; Naphthoquinones ; Pyridones ; Rats ; Rats, Sprague-Dawley ; Reproducibility of Results ; Sodium
-
References:
-
Drug Des Devel Ther. 2019 Sep 20;13:3343-3355. (PMID: 31571835)
J Adv Pract Oncol. 2022 Mar;13(2):158-163. (PMID: 35369397)
Pharmacol Res. 2010 Sep;62(3):207-27. (PMID: 20399862)
Int J Mol Sci. 2021 Mar 09;22(5):. (PMID: 33803472)
Biomed Res Int. 2021 Feb 23;2021:6636266. (PMID: 33688498)
BMC Pharmacol Toxicol. 2016 Nov 14;17(1):50. (PMID: 27839515)
Pharmaceutics. 2021 May 12;13(5):. (PMID: 34066184)
Drugs. 2020 Apr;80(5):513-521. (PMID: 32166598)
Syst Rev. 2020 Jan 6;9(1):1. (PMID: 31907078)
Eur J Clin Pharmacol. 2019 Sep;75(9):1237-1248. (PMID: 31154477)
Drug Des Devel Ther. 2021 Nov 30;15:4865-4873. (PMID: 34876808)
Sci Rep. 2016 Jun 22;6:28482. (PMID: 27329697)
Evid Based Complement Alternat Med. 2021 Nov 26;2021:4181196. (PMID: 34868331)
Int J Mol Sci. 2021 Jun 25;22(13):. (PMID: 34202294)
J Pharm Policy Pract. 2021 Nov 29;14(1):98. (PMID: 34844645)
Transl Cancer Res. 2020 Feb;9(2):556-564. (PMID: 35117400)
Front Pharmacol. 2022 Apr 04;13:876183. (PMID: 35444531)
Drug Des Devel Ther. 2019 Apr 23;13:1289-1300. (PMID: 31118568)
Biomed Res Int. 2020 Dec 1;2020:6940953. (PMID: 33344645)
Ther Adv Hematol. 2021 May 27;12:20406207211015882. (PMID: 34104370)
Cancer Sci. 2021 Sep;112(9):3627-3635. (PMID: 34159682)
Cancer Sci. 2021 Nov;112(11):4604-4616. (PMID: 34449935)
Cancer Sci. 2021 Mar;112(3):1123-1131. (PMID: 33492746)
-
Contributed Indexing:
-
Keywords: UPLC-MS/MS; herb-drug interactions; pharmacokinetics; plumbagin; tazemetostat
-
Substance Nomenclature:
-
0 (Acetonitriles)
0 (Benzamides)
0 (Biphenyl Compounds)
0 (Morpholines)
0 (Naphthoquinones)
0 (Pyridones)
9NEZ333N27 (Sodium)
K679OBS311 (Carboxymethylcellulose Sodium)
Q40W93WPE1 (tazemetostat)
YAS4TBQ4OQ (plumbagin)
-
Entry Date(s):
-
Date Created: 20221006 Date Completed: 20221007 Latest Revision: 20221011
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC9529013
-
DOI:
-
10.2147/DDDT.S384156
-
PMID:
-
36199632
-
Objective: A sensitive and rapid UPLC-MS/MS method for determination of tazemetostat in rat plasma was developed, and the pharmacokinetics of herb-drug interactions (HDIs) of plumbagin (PLB) and tazemetostat was investigated.
Methods: After the rat plasma samples were precipitated by acetonitrile, tazemetostat and verubecestat (ISTD) were detected. Gradient elution was performed with 0.1% formic acid and acetonitrile as mobile phases. The multi-reaction monitoring was used with ESI+ source, and the ion pairs for tazemetostat and ISTD were m/z 573.12→135.99 and m/z 410.10→124.00, respectively. 12 SD rats were randomly divided into the control group and the experimental group, 6 rats in each group. The rats in the experimental group were given PLB 100 mg/kg by gavage once a day for 7 consecutive days. The rats in the control group were given the same amount of 0.1% sodium carboxymethyl cellulose solution by gavage once a day for 7 consecutive days. At the seventh day, tazemetostat (80 mg/kg) was given and the blood was collected at different time points. The main parameters of pharmacokinetics were calculated and the herb-drug interactions (HDIs) were evaluated.
Results: In the calibrated range of 1-1000 ng/mL, tazemetostat had a good linearity. The extraction recovery was more than 84%, and the RSD of intra-batch and inter-batch precision were both less than 15%. The C max of tazemetostat in the experimental group was 32.48% higher than that in the control group, and the AUC (0-t) and AUC (0-∞) of tazemetostat in the experimental group were 46.24% and 46.67% higher than that in the control group, respectively, and the t 1/2 was prolonged from 10.56 h to 11.73 h.
Conclusion: A simple, rapid and sensitive UPLC-MS/MS method for the determination of tazemetostat in rat plasma was established. PLB can inhibit the metabolism of tazemetostat and increase the plasma exposure of tazemetostat in rats.
Competing Interests: The authors state that there is no conflict of interest in the publication of this paper.
(© 2022 Li et al.)
